DIA Conference to Explore Components of Risk Management Plans As They Apply to Medicinal Products, Therapeutic Biologics and Vaccines

Horsham, PA (Vocus) November 6, 2009

Expert speakers from industry, Health Canada, EMEA, FDA, and PMDA will lead presentations at the 2nd DIA Conference on Harmonization of Risk Management Plans to be held December 10-11, 2009 in Washington, DC.

This conference will explore the essential components of RMP as they apply to medicinal products, therapeutic biologics, and vaccines with a focus on real and potential risks of products, which may be made available to patients and healthcare providers in different regions of the world. Sessions will include:

•     Risk Management Plans: What Do They Mean and What Are the Requirements for Each Region?
•     Risk Management Plans: What Have We Learned from RMPs About Managing Product Risks?
•     Developing an Harmonized Risk Management Plan
•     Successes and Opportunities for Harmonized Risk Management Plans
•     Risk Management Plans Town Meeting
•     Future Developments of RMPs and REMS

“The 2nd DIA Conference on Harmonization of Risk Management Plans will bring together global regulators and industry representatives to lead hands-on exercises and didactic presentations and to participate in panel discussions,” explains Program Chair William W. Gregory, Director, Safety and Risk Management, Pfizer Inc. “They will discuss why RMPs are important to your organization from a global regulatory perspective, the pros and cons of a global vs. local approach to developing RMPs, how an harmonized RMP can promote efficient, evidence-based decision-making to support the best use of marketed products, and how to develop an harmonized approach to creating an RMP.”

Register for the 2nd DIA Conference on Harmonization of Risk Management Plans.

About the Drug Information Association (DIA):
A non-profit, neutral, multidisciplinary, global, member-driven association, DIA serves more than 30,000 professionals involved in the biopharmaceutical industry, academia, research organizations and governmental bodies worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of drug development and medical product lifecycle management. DIA is led by its volunteer Board of Directors and executive management team, has headquarters in Horsham, PA, USA, and offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China. For more information, visit http://www.diahome.org or call 215-442-6100.

Contact:
Joe Krasowski
DIA
+1-215-293-5812

###